Table 5.
High density lipoprotein cholesterol (HDL-C) contents in blood samples.
| HDL | 0D | 6D | 18D | 24D | 30D | 42D |
|---|---|---|---|---|---|---|
| A | 59.94 ± 32.45 | 94.03 ± 29.81 | 64.19 ± 24.53 | 43.87 ± 8.363 | 56.49 ± 14.07 | 45.17 ± 10.13 |
| B | 87.52 ± 25.16* | 231.0 ± 58.91*** | 82.43 ± 16.51* | 103.2 ± 35.14*** | 120.6 ± 40.79*** | 159.5 ± 67.11*** |
| C | 70.63 ± 25.64 | 184.7 ± 53.03*** | 85.64 ± 21.35* | 114.6 ± 65.55** | 151.1 ± 43.02** | 134.6 ± 51.15*** |
| D | 68.16 ± 18.51 | 203.2 ± 54.77*** | 146.9 ± 29.29∗∗∗, ### | 91.30 ± 19.25*** | 151.5 ± 30.35*** | 154.2 ± 58.52*** |
| E | 84.37 ± 20.96* | 175.0 ± 52.67∗∗∗, # | 159.2 ± 36.76∗∗∗, ### | 104.7 ± 43.40*** | 164.3 ± 55.30*** | 162.7 ± 64.15*** |
| F | 49.46 ± 13.40† | 142.6 ± 63.33∗, ## | 143.8 ± 29.48∗∗∗, ###,††† | 106.0 ± 47.44*** | 182.1 ± 79.76*** | 148.3 ± 50.91*** |
| G | 68.74 ± 13.56 | 157.5 ± 70.00∗∗, # | 124.7 ± 44.38∗∗∗, ## | 101.6 ± 34.80*** | 193.7 ± 70.87∗∗∗, # | 120.1 ± 54.00*** |
| H | 65.84 ± 23.89 | 240.9 ± 59.83∗∗∗,† | 131.4 ± 68.25∗∗, # | 103.5 ± 34.80*** | 191.2 ± 74.25∗∗∗, # | 173.9 ± 63.37*** |
| I | 57.36 ± 10.28 | 167.1 ± 49.01∗∗∗, ## | 65.42 ± 25.85 | 100.8 ± 41.64*** | 167.7 ± 68.80*** | 148.3 ± 86.91*** |
| J | 72.06 ± 29.60 | 148.3 ± 60.49∗, ## | 113.4 ± 29.27∗∗∗, ## | 126.1 ± 32.71*** | 189.2 ± 56.13∗∗∗, ## | 147.5 ± 76.78*** |
High density lipoprotein cholesterol (HDL-C) contents were assayed by assay kits as described in the text.
Values were mean ± SD (n = 12) and expressed in mg/dL.
The * indicates a significant difference compared with control group, *P < 0.05, **P < 0.01, ***P < 0.001.
The # indicates a significant difference compared with model group, # P < 0.05, ## P < 0.01, ### P < 0.001.
The † indicates a significant difference compared with PMR group (same dosage level, F compared with C, G compared to D, H compared to E), † P < 0.05, ††† P < 0.001.